Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conven...

Descripción completa

Detalles Bibliográficos
Autores principales: Macedo, Thais Rodrigues, de Queiroz, Genilson Fernandes, Casagrande, Thaís Andrade Costa, Alexandre, Pâmela Almeida, Brandão, Paulo Eduardo, Fukumasu, Heidge, Melo, Samanta Rios, Dagli, Maria Lucia Zaidan, Pinto, Ana Carolina B. C. Fonseca, Matera, Julia Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834544/
https://www.ncbi.nlm.nih.gov/pubmed/35159380
http://dx.doi.org/10.3390/cells11030571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834544/
https://www.ncbi.nlm.nih.gov/pubmed/35159380
http://dx.doi.org/10.3390/cells11030571

Ejemplares similares